BW Gestao de Investimentos Ltda. Reduces Position in Perrigo Company plc $PRGO

BW Gestao de Investimentos Ltda. decreased its stake in shares of Perrigo Company plc (NYSE:PRGO) by 19.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,277,069 shares of the company’s stock after selling 305,050 shares during the quarter. BW Gestao de Investimentos Ltda.’s holdings in Perrigo were worth $17,777,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its position in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares in the last quarter. Kestra Investment Management LLC boosted its holdings in shares of Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Perrigo by 89.1% during the third quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after purchasing an additional 838 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after purchasing an additional 1,014 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after purchasing an additional 1,527 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Down 2.8%

Shares of NYSE PRGO opened at $10.75 on Tuesday. Perrigo Company plc has a 1 year low of $9.23 and a 1 year high of $28.43. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -0.82, a PEG ratio of 1.30 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The stock’s 50-day simple moving average is $10.99 and its 200-day simple moving average is $12.60.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities analysts anticipate that Perrigo Company plc will post 2.12 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be paid a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 10.8%. The ex-dividend date is Friday, May 29th. Perrigo’s payout ratio is presently -8.85%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PRGO. Weiss Ratings cut Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Canaccord Genuity Group reduced their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.